Spojené štáty - angličtina - NLM (National Library of Medicine)

breckenridge pharmaceutical, inc. - oxaliplatin (unii: 04zr38536j) (oxaliplatin - unii:04zr38536j) - oxaliplatin 50 mg in 10 ml - oxaliplatin injection, usp used in combination with infusional 5-fluorouracil/leucovorin, is indicated for: - adjuvant treatment of stage iii colon cancer in patients who have undergone complete resection of the primary tumor. - treatment of advanced colorectal cancer. oxaliplatin injection, usp should not be administered to patients with a history of known allergy to oxaliplatin injection, usp or other platinum compounds [see warnings and precautions (5.1)] . pregnancy category d based on direct interaction with dna, oxaliplatin injection, usp may cause fetal harm when administered to a pregnant woman. there are no adequate and well-controlled studies of oxaliplatin injection, usp in pregnant women. reproductive toxicity studies in rats demonstrated adverse effects on fertility and embryo-fetal development at maternal doses that were below the recommended human dose based on body surface area. if this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - oxaliplatin, quantity: 50 mg - injection, solution - excipient ingredients: lactose monohydrate; water for injections - oxaliplatin, in combination with fluorouracil and folinic acid, is indicated for: - adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of the primary tumour; - treatment of advanced colorectal cancer

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

viatris limited - oxaliplatin 50mg;   - powder for infusion - 50 mg - active: oxaliplatin 50mg   excipient: lactose monohydrate nitrogen water for injection - oxaliplatin, in combination with 5-fluorouracil and folinic acid, is indicated for adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of the primary tumour.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - oxaliplatin, quantity: 200 mg - injection, solution - excipient ingredients: lactose monohydrate; water for injections - oxaliplatin, in combination with fluorouracil and folinic acid, is indicated for: - adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of the primary tumour; - treatment of advanced colorectal cancer

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - oxaliplatin, quantity: 100 mg - injection, solution - excipient ingredients: water for injections; lactose monohydrate - oxaliplatin, in combination with fluorouracil and folinic acid, is indicated for: - adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of the primary tumour; - treatment of advanced colorectal cancer

Izrael - angličtina - Ministry of Health

tzamal bio-pharma ltd - oxaliplatin - powder for solution for infusion - oxaliplatin 100 mg/vial - oxaliplatin - oxaliplatin - oxaliplatin in combination with 5-fluorouracil (5-fu) and folinic acid (fa) is indicated for: • adjuvant treatment of stage iii (duke‘s c) colon cancer after complete resection of primary tumor. • treatment of metastatic colorectal cancer. oxaliplatin in combination with leucovorin, irinotecan and 5-fluorouracil is indicated for the first-line treatment of patients with metastatic pancreatic adenocarcinoma (based on nccn guidelines, version 2.2014).

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - oxaliplatin, quantity: 50 mg - injection, concentrated - excipient ingredients: water for injections - oxaliplatin is indicated for adjuvant treatment of stage iii (duke?s c) colon cancer, in combination with fluoropyrimidine agent.,oxaliplatin in combination with fluorouracil and folinic acid is indicated for the treatment of advanced colorectal cancer.,oxaliplatin in combination with capecitabine, with or without bevacizumab, is indicated for the treatment of patients with metastatic colorectal cancer.,oxaliplatin in combination with epirubicin and either capecitabine or fluorouracil, is indicated for: the treatment of patients with advanced oesophagogastric cancer

Spojené kráľovstvo - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

actavis uk ltd - oxaliplatin - powder for solution for infusion - 50mg

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - oxaliplatin, quantity: 200 mg - injection, concentrated - excipient ingredients: water for injections - oxaliplatin is indicated for adjuvant treatment of stage iii (duke?s c) colon cancer, in combination with fluoropyrimidine agent.,oxaliplatin in combination with fluorouracil and folinic acid is indicated for the treatment of advanced colorectal cancer.,oxaliplatin in combination with capecitabine, with or without bevacizumab, is indicated for the treatment of patients with metastatic colorectal cancer.,oxaliplatin in combination with epirubicin and either capecitabine or fluorouracil, is indicated for: the treatment of patients with advanced oesophagogastric cancer

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - oxaliplatin, quantity: 100 mg - injection, concentrated - excipient ingredients: water for injections - oxaliplatin is indicated for adjuvant treatment of stage iii (duke?s c) colon cancer, in combination with fluoropyrimidine agent.,oxaliplatin in combination with fluorouracil and folinic acid is indicated for the treatment of advanced colorectal cancer.,oxaliplatin in combination with capecitabine, with or without bevacizumab, is indicated for the treatment of patients with metastatic colorectal cancer.,oxaliplatin in combination with epirubicin and either capecitabine or fluorouracil, is indicated for: the treatment of patients with advanced oesophagogastric cancer